![]() ![]() | GUREGHIAN, V., HERBST, H., KOZAR, I., MIHAJLOVIC, K., Malod-Dognin, N., Ceddia, G., ANGELI, C., WURTH-MARGUE, C., RANDIC, T., PHILIPPIDOU, D., TETSI NOMIGNI, M., HEMEDAN, A., TRANCHEVENT, L.-C., LONGWORTH, J., Bauer, M., BADKAS, A., GAIGNEAUX, A., Muller, A., OSTASZEWSKI, M., ... KREIS, S. (October 2023). A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma. Cancer Gene Therapy, 30 (10), 1330 - 1345. doi:10.1038/s41417-023-00640-z ![]() |
![]() ![]() | Rigg, E., Wang, J., Xue, Z., Lunavat, T. R., Liu, G., Hoang, T., Parajuli, H., Han, M., Bjerkvig, R., Nazarov, P. V., Nicot, N., KREIS, S., WURTH-MARGUE, C., TETSI NOMIGNI, M., Utikal, J., Miletic, H., Sundstrøm, T., Ystaas, L. A. R., Li, X., & Thorsen, F. (October 2023). Inhibition of extracellular vesicle-derived miR-146a-5p decreases progression of melanoma brain metastasis via Notch pathway dysregulation in astrocytes. Journal of Extracellular Vesicles, 12 (10), 12363. doi:10.1002/jev2.12363 ![]() |
![]() ![]() | Bintener, T., PIRES PACHECO, M. I., PHILIPPIDOU, D., MARGUE, C., KISHK, A., Del Mistro, G., Di Leo, L., MOSCARDO GARCIA, M., HALDER, R., SINKKONEN, L., De Zio, D., KREIS, S., Kulms, D., & SAUTER, T. (26 July 2023). Metabolic modelling-based in silico drug target prediction identifies six novel repurposable drugs for melanoma. Cell Death and Disease, 14 (468). doi:10.1038/s41419-023-05955-1 ![]() |
![]() ![]() | RANDIC, T., MAGNI, S., PHILIPPIDOU, D., Margue, C., GRZYB, K., PREIS, J. R., WROBLEWSKA, J. P., NAZAROV, P., MITTELBRONN, M., FRAUENKNECHT, K., SKUPIN, A., & KREIS, S. (25 July 2023). Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response. Cell Reports, 42 (7), 112696. doi:10.1016/j.celrep.2023.112696 ![]() |
![]() ![]() | WROBLEWSKA, J. P., Lach, M. S., Rucinski, M., Piotrowski, I., Galus, L., Suchorska, W. M., KREIS, S., & Marszałek, A. (2022). MiRNAs from serum-derived extracellular vesicles as biomarkers for uveal melanoma progression. Frontiers in Cell and Developmental Biology. doi:10.3389/fcell.2022.1008901 ![]() |
![]() ![]() | TOLLE, F., Umansky, V., Utikal, J., KREIS, S., & BRECHARD, S. (23 June 2021). Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies? International Journal of Molecular Sciences, 22 (13), 6744. doi:10.3390/ijms22136744 ![]() |
![]() ![]() | RANDIC, T., KOZAR, I., MARGUE, C., Utikal, J., & KREIS, S. (29 May 2021). NRAS mutant melanoma: Towards better therapies. Cancer Treatment Reviews, 99. doi:10.1016/j.ctrv.2021.102238 ![]() |
![]() ![]() | KOZAR, I., PHILIPPIDOU, D., MARGUE, C., Gay, L., Renne, R., & KREIS, S. (2021). Cross-Linking Ligation and Sequencing of Hybrids (qCLASH) Reveals an Unpredicted miRNA Targetome in Melanoma Cells. Cancers. doi:10.3390/cancers13051096 ![]() |
![]() ![]() | KIRCHMEYER, M., SERVAIS, F., GINOLHAC, A., Nazarov, P. V., MARGUE, C., PHILIPPIDOU, D., Nicot, N., BEHRMANN, I., HAAN, C., & KREIS, S. (2020). Systematic transcriptional profiling of responses to STAT1- and STAT3- activating cytokines in different cancer types. Journal of Molecular Biology. doi:10.1016/j.jmb.2020.09.011 ![]() |
![]() ![]() | Walbrecq, G., MARGUE, C., BEHRMANN, I., & KREIS, S. (2020). Distinct Cargos of Small Extracellular Vesicles Derived from Hypoxic Cells and Their Effect on Cancer Cells. International Journal of Molecular Sciences. doi:10.3390/ijms21145071 ![]() |
![]() ![]() | Walbrecq, G., Lecha, O., GAIGNEAUX, A., Fougeras, M. R., PHILIPPIDOU, D., MARGUE, C., TETSI NOMIGNI, M., Bernardin, F., DITTMAR, G., BEHRMANN, I., & KREIS, S. (2020). Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles. Cancers. doi:10.3390/cancers12030692 ![]() |
![]() ![]() | Nazarov, P. V., Wienecke-Baldacchino, A. K., Zinovyev, A., Czerwińska, U., Muller, A., Nashan, D., Dittmar, G., Azuaje, F., & KREIS, S. (18 September 2019). Deconvolution of Transcriptomes and miRNomes by Independent Component Analysis Provides Insights Into Biological Processes and Clinical Outcomes of Melanoma Patients. BMC Medical Genomics, 12 (1) (132). doi:10.1186/s12920-019-0578-4 ![]() |
![]() ![]() | KOZAR, I., MARGUE, C., Rothengatter, S., HAAN, C., & KREIS, S. (15 February 2019). Many ways to resistance: How melanoma cells evade targeted therapies. Biochimica et Biophysica Acta. Reviews on Cancer, 1871 (2), 313-322. doi:10.1016/j.bbcan.2019.02.002 ![]() |
![]() ![]() | MARGUE, C., PHILIPPIDOU, D., KOZAR, I., CESI, G., FELTEN, P., Kulms, D., LETELLIER, E., HAAN, C., & KREIS, S. (February 2019). Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. Journal of Experimental and Clinical Cancer Research, 38 (1). doi:10.1186/s13046-019-1038-x ![]() |
![]() ![]() | SERVAIS, F., KIRCHMEYER, M., HAMDORF, M., MINOUNGOU, W. N., Rose-John, S., KREIS, S., HAAN, C., & BEHRMANN, I. (2019). Modulation of the IL-6 signaling pathway in liver cells by miRNAs targeting gp130, JAK1 and/or STAT3. Molecular Therapy: Nucleic Acids, 16, 419-433. doi:10.1016/j.omtn.2019.03.007 ![]() |
![]() ![]() | Cesi, G., PHILIPPIDOU, D., KOZAR, I., Kim, Y. J., Bernardin, F., Van Niel, G., Wienecke-Baldacchino, A., FELTEN, P., LETELLIER, E., Dengler, S., Nashan, D., HAAN, C., & KREIS, S. (2018). A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. Molecular Cancer, (17:145). doi:10.1186/s12943-018-0886-x ![]() |
![]() ![]() | Bauer, A. S., Nazarov, P. V., Giese, N. A., Beghelli, S., Heller, A., Greenhalf, W., Costello, E., Muller, A., Bier, M., Strobel, O., Hackert, T., Vallar, L., Scarpa, A., Büchler, M. W., Neoptolemos, J. P., KREIS, S., & Hoheisel, J. D. (01 March 2018). Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. International Journal of Cancer, 142 (5), 1010–1021. doi:10.1002/ijc.31087 ![]() |
![]() ![]() | ROLVERING, C., ZIMMER, A. D., GINOLHAC, A., MARGUE, C., KIRCHMEYER, M., SERVAIS, F., Hermanns, H. M., Hergovits, S., Nazarov, P. V., Nicot, N., KREIS, S., HAAN, S., BEHRMANN, I., & HAAN, C. (2018). The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by a-PD-L1 or a-IL6 antibodies. Journal of Leukocyte Biology, 104, 969-985. doi:10.1002/JLB.MA1217-495R ![]() |
![]() ![]() | Kirchmeyer, M., SERVAIS, F., Hamdorf, M., Nazarov, P. V., GINOLHAC, A., HALDER, R., Vallar, L., Glanemann, M., Rubie, C., Lammert, F., KREIS, S., & BEHRMANN, I. (2018). Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets. Journal of Leukocyte Biology. doi:10.1002/JLB.MA1217-499RR ![]() |
![]() ![]() | Mgrditchian, T., Arakelian, T., Paggetti, J., Noman, M., Viry, E., Moussay, E., Van Moer, K., KREIS, S., Guerin, C., Buart, S., Robert, C., Borg, C., Vielh, P., Chouaib, S., Berchem, G., & Janji, B. (31 October 2017). Targeting autophagy inhibits growth by enhancing NK cells infiltration in a CCL5-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 114 ((44)), 9271-E9279. doi:10.1073/pnas.1703921114 ![]() |
![]() ![]() | CESI, G., WALBRECQ, G., ZIMMER, A. D., KREIS, S., & HAAN, C. (08 June 2017). ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Molecular Cancer, 8 (june). doi:10.1186/s12943-017-0667-y ![]() |
![]() ![]() | KREIS, S., KOZAR, I., CESI, G., MARGUE, C., & PHILIPPIDOU, D. (2017). Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. Biochimica et Biophysica Acta. doi:10.1016/j.bbagen.2017.04.005 ![]() |
![]() ![]() | Keller, A., KREIS, S., Leidinger, P., Maixner, F., Ludwig, N., Backes, C., Galata, V., Guerriero, G., Fehlmann, T., Franke, A., Meder, B., Zink, A., & Meese, E. (26 December 2016). miRNAs in ancient tissue specimens of the Tyrolean Iceman. Molecular Biology and Evolution, 34 (4), 793-801. doi:10.1093/molbev/msw291 ![]() |
![]() ![]() | Heulot, M., Chevalier, N., Puyal, J., MARGUE, C., Michel, S., KREIS, S., Kulms, D., Barras, D., Nahimana, A., & Widmann, C. (27 September 2016). The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner. Oncotarget, 7 (39). doi:10.18632/oncotarget.11841 ![]() |
![]() ![]() | CESI, G., WALBRECQ, G., MARGUE, C., & KREIS, S. (10 June 2016). Transferring intercellular signals and traits between cancer cells: extracellular vesicles as "homing pigeons". Cell Communication and Signaling, 14 (1), 13. doi:10.1186/s12964-016-0136-z ![]() |
Reinsbach, S., WIENECKE, A., GINOLHAC, A., Vallar, L., Krishna, Krishna, A., Nazarov, P., MAY, P., & KREIS, S. (2016). “Melanomics”: analysis and integration of whole genomes, transcriptomes and miRNomes of primary melanoma patients. European Journal of Cancer, 61 (Suppl.1), 32. doi:10.1016/S0959-8049(16)61101-2 |
![]() ![]() | BEHRMANN, I., MARGUE, C., & KREIS, S. (2015). Circulating microRNAs as candidate biomarkers for the surveillance of melanoma patients. EBioMedicine. doi:10.1016/j.ebiom.2015.07.015 ![]() |
KAYSEN, A., BUSCHART, A., MAY, P., LACZNY, C. C., NARAYANASAMY, S., Graf, N., Simon, A., Bittenbring, J., KREIS, S., SCHNEIDER, J., & WILMES, P. (June 2015). Dynamic change of host gastrointestinal microbiome and immune status in relation to mucosal barrier effects during chemotherapy and immune ablative intervention in humans [Poster presentation]. The Human Microbiome, Heidelberg, Germany. |
KAYSEN, A., HEINTZ, A., LEBRUN, L., Graf, N., Simon, A., Bittenbring, J., KREIS, S., SCHNEIDER, J., & WILMES, P. (March 2015). Changes in the human gastrointestinal microbiome during cancer treatments [Poster presentation]. 5th International Human Microbiome Congress, Luxembourg-City, Luxembourg. |
![]() ![]() | SERVAIS, F., Kirchmeyer, M., HAMDORF, M., HAAN, C., Casper, M., Lammert, F., Nazarov, P., Vallar, L., KREIS, S., & BEHRMANN, I. (2015). ID: 194: Role of microRNAs in signal transduction pathways of the inflammatory cytokine Interleukin-6: Relevance for liver diseases. Cytokine, 76 (1), 99. doi:10.1016/j.cyto.2015.08.198 ![]() |
![]() ![]() | MARGUE, C., REINSBACH, S., PHILIPPIDOU, D., BEAUME, N., Walters, C., SCHNEIDER, J., Nashan, D., BEHRMANN, I., & KREIS, S. (2015). Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget, 6 (14), 12110-27. doi:10.18632/oncotarget.3661 ![]() |
KAYSEN, A., HEINTZ, A., LEBRUN, L., Graf, N., Simon, A., Bittenbring, J., KREIS, S., SCHNEIDER, J., & WILMES, P. (April 2014). Dynamic change of host gastrointestinal microbiome and immune status in relation to mucosal barrier effects during chemotherapy and immune ablative intervention in humans [Poster presentation]. Exploring Human Host-Microbiome Interactions in Health and Disease. |
![]() ![]() | MARGUE, C., PHILIPPIDOU, D., REINSBACH, S., SCHMITT, M., BEHRMANN, I., & KREIS, S. (05 September 2013). New Target Genes of MITF-Induced microRNA-211 Contribute to Melanoma Cell Invasion. PLoS ONE, 8 (9). doi:10.1371/journal.pone.0073473 ![]() |
![]() ![]() | Nazarov, P. V. A., REINSBACH, S., Muller, A. A., Nicot, N. A., PHILIPPIDOU, D., Vallar, L. A., & KREIS, S. (2013). Interplay of microRNAs, transcription factors and target genes: Linking dynamic expression changes to function. Nucleic Acids Research, 41 (5), 2817-2831. doi:10.1093/nar/gks1471 ![]() |
![]() ![]() | Schmitt, M., MARGUE, C., BEHRMANN, I., & KREIS, S. (2012). MiRNA-29: A microRNA family with tumor-suppressing and immune-modulating properties. Current Molecular Medicine, 13 (4), 572-585. doi:10.2174/1566524011313040009 ![]() |
![]() ![]() | REINSBACH, S., Nazarov, P. V., PHILIPPIDOU, D., Schmitt, M., WIENECKE, A., Muller, A., Vallar, L., BEHRMANN, I., & KREIS, S. (2012). Dynamic regulation of microRNA expression following interferonγ- induced gene transcription. RNA Biology, 9 (7), 987-989. doi:10.4161/rna.20494 ![]() |
![]() ![]() | Schmitt, M. J., PHILIPPIDOU, D., REINSBACH, S., MARGUE, C., WIENECKE-BALDACCHINO, A., Nashan, D., BEHRMANN, I., & KREIS, S. (2012). Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Communication and Signaling, 10. doi:10.1186/1478-811X-10-41 ![]() |
![]() ![]() | PHILIPPIDOU, D., SCHMITT, M., Moser, D., MARGUE, C., Nazarov, P. V., Muller, A., Vallar, L., Nashan, D., BEHRMANN, I., & KREIS, S. (2010). Signatures of MicroRNAs and selected MicroRNA target genes in human melanoma. Cancer Research, 70 (10), 4163-4173. doi:10.1158/0008-5472.CAN-09-4512 ![]() |
![]() ![]() | MARGUE, C., & KREIS, S. (2010). IL-24: Physiological and supraphysiological effects on normal and malignant cells. Current Medicinal Chemistry, 17 (29), 3318-3326. doi:10.2174/092986710793176311 ![]() |
![]() ![]() | KREIS, S., PHILIPPIDOU, D., MARGUE, C., & BEHRMANN, I. (10 May 2008). IL-24: a classic cytokine and/or a potential cure for cancer? Journal of Cellular and Molecular Medicine, 12 (6A), 2505-2510. doi:10.1111/j.1582-4934.2008.00372.x ![]() |
![]() ![]() | KREIS, S., Munz, G. A., HAAN, S., Heinrich, P. C., & BEHRMANN, I. (2008). Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Molecular Cancer Research, 5 (12), 1331-41. doi:10.1158/1541-7786.MCR-07-0317 ![]() |
![]() ![]() | KREIS, S., PHILIPPIDOU, D., MARGUE, C., ROLVERING, C., HAAN, C., Dumoutier, L., Renauld, J.-C., & BEHRMANN, I. (2007). Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS ONE, 2 (12), 1300. doi:10.1371/journal.pone.0001300 ![]() |
![]() ![]() | HAAN, C., KREIS, S., MARGUE, C., & BEHRMANN, I. (November 2006). Jaks and cytokine receptors - an intimate relationship. Biochemical Pharmacology, 72 (11), 1538-46. doi:10.1016/j.bcp.2006.04.013 ![]() |
KREIS, S., Schönfeld, H.-J. B., Melchior, C. A., Steiner, B. B. C., & Kieffer, N. A. (2005). The intermediate filament protein vimentin binds specifically to a recombinant integrin α2/β1 cytoplasmic tail complex and co-localizes with native α2/β1 in endothelial cell focal adhesions. Experimental Cell Research, 305 (1), 110-121. doi:10.1016/j.yexcr.2004.12.023 ![]() |
![]() ![]() | Tremuth, L. A., KREIS, S., Melchior, C., Hoebeke, J., Rondé, P., PLANÇON, S., Takeda, K., & KIEFFER, N. (2004). A fluorescence cell biology approach to map the second integrin-binding site of talin to a 130-amino acid sequence within the rod domain. Journal of Biological Chemistry, 279 (21), 22258-22266. doi:10.1074/jbc.M400947200 ![]() |
Melchior, C. A., KREIS, S., Janji, B. B., & Kieffer, N. A. (2002). Promoter characterization and genomic organization of the gene encoding integrin-linked kinase 1. Biochimica et Biophysica Acta-Gene Structure and Expression, 1575 (1-3), 117-122. doi:10.1016/S0167-4781(02)00247-6 ![]() |
Hartter, H. K., Oyedele, O. I., Dietz, K., KREIS, S., Hoffman, J. P., & Muller, C. (2000). Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatric Infectious Disease Journal, 19 (7), 635-641. doi:10.1097/00006454-200007000-00010 ![]() |
Fack, F., Deroo, S., KREIS, S., & Muller, C. (2000). Heteroduplex mobility assay (HMA) pre-screening: An improved strategy for the rapid identification of inserts selected from phage-displayed peptide libraries. Molecular Diversity, 5 (1), 7-12. doi:10.1023/A:1011318710547 ![]() |
Truong, A. T., KREIS, S., Ammerlaan, W., Hartter, H. K., Adu, F., Omilabu, S. A., Oyefolu, A. O., Berbers, G. A. M., & Muller, C. (1999). Genotypic and antigenic characterization of hemagglutinin proteins of African measles virus isolates. Virus Research, 62 (1), 89-95. doi:10.1016/S0168-1702(99)00072-6 ![]() |
Vardas, E. A. B., & KREIS, S. (1999). Isolation of measles virus from a naturally-immune, asymptomatically re-infected individual. Journal of Clinical Virology, 13 (3), 173-179. doi:10.1016/S1386-6532(99)00026-8 ![]() |
Vardas, E. A. D., Leary, P. M. B., Yeats, J. C., Badrodien, W. B., & KREIS, S. (1999). Case report and molecular analysis of subacute sclerosing panencephalitis in a South African child. Journal of Clinical Microbiology, 37 (3), 775-777. doi:10.1128/jcm.37.3.775-777.1999 ![]() |
KREIS, S., & Schoub, B. D. (1998). Partial amplification of the measles virus nucleocapsid gene from stored sera and cerebrospinal fluids for molecular epidemiological studies. Journal of Medical Virology, 56 (2), 174-177. doi:10.1002/(SICI)1096-9071(199810)56:2<174::AID-JMV12>3.0.CO;2-G ![]() |
KREIS, S., & Whistler, T. (1997). Rapid identification of measles virus strains by the heteroduplex mobility assay. Virus Research, 47 (2), 47(2):197-203. doi:10.1016/S0168-1702(96)01413-X ![]() |
Vardas, E., Andre, M., KREIS, S., Zachariades, N., & Schoub, B. (1997). Measles virus transmission from infected to immune individuals - Implications for measles control and elimination. South African Medical Journal, 87 (12), 1709. ![]() |
KREIS, S., Vardas, E., & Whistler, T. (1997). Sequence analysis of the nucleocapsid gene of measles virus isolates from South Africa identifies a new genotype. Journal of General Virology, 78 (7), 1581-1587. doi:10.1099/0022-1317-78-7-1581 ![]() |